# NCT06892548 (NCT06892548)

> A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06892548
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: BioNTech SE
- Conditions: Advanced Lung Cancer
- Interventions: BNT324; BNT327
- Enrollment: 594
- Primary outcome: Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose level
- Primary outcome: Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose level
- Primary outcome: Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose level
- Primary outcome: Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment arm
- Primary outcome: Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment arm
- Primary outcome: Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment arm
- Primary outcome: Part 2 cohorts 3-7 - ORR by cohort

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06892548